Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 14/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17443931 | 0.91 | DGAT2 (0.38) | PDE4BNPC1RAB9ADGAT2 | |
| SCHEMBL20594226 | 0.90 | RAB9A (0.40) | PDE4BNPC1RAB9ADGAT2 | |
| SCHEMBL17443644 | 0.90 | PDE4B (0.40) | PDE4BDGAT2 | |
| SCHEMBL17443778 | 0.89 | PDE4B (0.52) | PDE4BDGAT2 | |
| SCHEMBL17443784 | 0.88 | PDE4B (0.43) | PDE4B | |
| SCHEMBL17443833 | 0.87 | PDE4B (0.56) | PDE4B | |
| SCHEMBL17456970 | 0.86 | NPC1 (0.44) | PDE4BNPC1RAB9ADGAT2 | |
| SCHEMBL17456980 | 0.86 | NPSR1 (0.48) | PDE4BDGAT2 | |
| SCHEMBL17456895 | 0.86 | PDE4B (0.53) | PDE4B | |
| SCHEMBL17450580 | 0.85 | PDE4B (0.45) | PDE4BDGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3415509-A1 | NOVEL 2,5-SUBSTITUTED PYRIMIDINES AS PDE INHIBITORS | Grünenthal GmbH (DE) | 2018-12-19 | — | — | EP | disclosed |
| US-9315490-B2 | 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2016-04-19 | — | — | US | disclosed |
| US-20160024053-A1 | Novel 2,5-Substituted Pyrimidines | GRUENENTHAL GMBH (DE) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024053-A1 | Novel 2,5-Substituted Pyrimidines | PDE4B, PDE4A, PDE12 | PDE4B 1/4885NPC1 2794/4885RAB9A 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.